| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/ACPS.12717 |
| P698 | PubMed publication ID | 28260229 |
| P50 | author | Gordon Parker | Q5585645 |
| Gabriela Tavella | Q89409700 | ||
| P2093 | author name string | R K Graham | |
| P2860 | cites work | Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012 | Q26824955 |
| The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders | Q30583384 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania | Q34606256 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression | Q34616633 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 | ||
| The clinical management of bipolar disorder: a review of evidence-based guidelines | Q35559908 | ||
| Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders | Q35862776 | ||
| The dark side of bipolarity: detecting bipolar depression in its pleomorphic expressions | Q36039791 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies | Q36161335 | ||
| Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 | ||
| Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians? | Q38059983 | ||
| Rigour of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: systematic review | Q38284814 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
| Are the bipolar disorders best modelled categorically or dimensionally? | Q50535368 | ||
| Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. | Q50643348 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 515-526 | |
| P577 | publication date | 2017-03-05 | |
| P1433 | published in | Acta Psychiatrica Scandinavica | Q4033348 |
| P1476 | title | Is there consensus across international evidence-based guidelines for the management of bipolar disorder? | |
| P478 | volume | 135 |
| Q100766031 | Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study |
| Q97545831 | Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia |
| Q59336772 | Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision |
| Q64078164 | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
| Q57808967 | Rapid methods including network meta-analysis to produce evidence in clinical decision support: a decision analysis |
| Q88527763 | Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder |
| Q88462374 | Response to lithium has a neurobiological signature |
| Q46200157 | Systemic challenges in bipolar disorder management: A patient-centered approach. |
Search more.